Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate

Author: Benzinga Newsdesk | March 13, 2024 04:12pm
Spero Therapeutics (NASDAQ:SPRO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(0.10) by 1060 percent. This is a 74.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $73.524 million which beat the analyst consensus estimate of $18.633 million by 294.58 percent. This is a 54.98 percent increase over sales of $47.441 million the same period last year.

Posted In: SPRO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist